IMUNON to Host 2026 R&D Day Highlighting Phase 3 OVATION 3 Trial and the Clinical Potential of IMNN-001
IMUNON announced it will host an R&D Day on September 23, 2026, in New York City to provide updates on its Phase 3 OVATION 3 trial for IMNN-001. The event will feature presentations from management and oncology experts, including a patient sharing her experience with the IL-12 immunotherapy.
Key figures
- Drug dose
- 100 mg/m^2
- Rd day date
- September 23, 2026
- Ovation2 patients
- 112
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.